We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Protagen AG Appoints Bernhard Kirschbaum as New Board Member

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Protagen AG Appoints Bernhard Kirschbaum as New Board Member"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Protagen AG has announced that the former Head of Research and Early Development of Merck Serono, Dr. Bernhard Kirschbaum, has joined the company’s Supervisory Board. 

This news follows the recently announced strategic partnership between Protagen and QIAGEN, which will focus on pharma collaborations in the autoimmune space, an area where Dr. Kirschbaum has significant expertise.

Dr. Kirschbaum has served in executive positions at Hoechst, Aventis, Sanofi, and Merck Serono, and has a proven track record in preclinical and clinical R&D, with a special focus on autoimmune diseases and chronic inflammatory disorders. According to Dr. Kirschbaum, “Protagen offers a very solid, unique technology with broad application potential. It is of particular relevance for translational research, which remains a central topic in drug development. In many diseases, analyses at the protein level offer key insights and guidance on diseases status and drug development.” 

Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of CDx for autoimmune therapy, it is imperative that we have meaningful insight into the R&D processes and interfaces of big pharma. The profound expertise Dr. Kirschbaum will bring to this role will provide us with valuable guidance, which will enable us to effectively expand our business within the growing CDx field.”